Immix Biopharma (IMMX) Competitors $1.96 -0.04 (-2.00%) Closing price 09/17/2025 04:00 PM EasternExtended Trading$2.03 +0.07 (+3.78%) As of 08:40 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMX vs. AVIR, SXTC, HRTX, PBYI, SOPH, CRGX, PRQR, GNFT, AVTE, and TNYAShould you be buying Immix Biopharma stock or one of its competitors? The main competitors of Immix Biopharma include Atea Pharmaceuticals (AVIR), China SXT Pharmaceuticals (SXTC), Heron Therapeutics (HRTX), Puma Biotechnology (PBYI), SOPHiA GENETICS (SOPH), CARGO Therapeutics (CRGX), ProQR Therapeutics (PRQR), GENFIT (GNFT), Aerovate Therapeutics (AVTE), and Tenaya Therapeutics (TNYA). These companies are all part of the "pharmaceutical products" industry. Immix Biopharma vs. Its Competitors Atea Pharmaceuticals China SXT Pharmaceuticals Heron Therapeutics Puma Biotechnology SOPHiA GENETICS CARGO Therapeutics ProQR Therapeutics GENFIT Aerovate Therapeutics Tenaya Therapeutics Immix Biopharma (NASDAQ:IMMX) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends, media sentiment and valuation. Which has more risk and volatility, IMMX or AVIR? Immix Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Do analysts rate IMMX or AVIR? Immix Biopharma currently has a consensus target price of $8.00, indicating a potential upside of 308.16%. Atea Pharmaceuticals has a consensus target price of $6.00, indicating a potential upside of 106.19%. Given Immix Biopharma's higher probable upside, equities research analysts clearly believe Immix Biopharma is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immix Biopharma 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is IMMX or AVIR more profitable? Atea Pharmaceuticals' return on equity of -32.55% beat Immix Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Immix BiopharmaN/A -205.35% -110.63% Atea Pharmaceuticals N/A -32.55%-30.47% Which has better earnings and valuation, IMMX or AVIR? Immix Biopharma is trading at a lower price-to-earnings ratio than Atea Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmix BiopharmaN/AN/A-$21.61M-$0.77-2.55Atea PharmaceuticalsN/AN/A-$168.38M-$1.61-1.81 Does the media prefer IMMX or AVIR? In the previous week, Immix Biopharma had 10 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 11 mentions for Immix Biopharma and 1 mentions for Atea Pharmaceuticals. Immix Biopharma's average media sentiment score of 0.59 beat Atea Pharmaceuticals' score of 0.46 indicating that Immix Biopharma is being referred to more favorably in the media. Company Overall Sentiment Immix Biopharma Positive Atea Pharmaceuticals Neutral Do institutionals & insiders believe in IMMX or AVIR? 11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are owned by institutional investors. 55.4% of Immix Biopharma shares are owned by company insiders. Comparatively, 18.1% of Atea Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryImmix Biopharma beats Atea Pharmaceuticals on 7 of the 11 factors compared between the two stocks. Get Immix Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMX vs. The Competition Export to ExcelMetricImmix BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$57.67M$3.12B$5.74B$10.30BDividend YieldN/A2.37%5.86%4.62%P/E Ratio-2.5521.0376.8026.52Price / SalesN/A249.02448.8087.93Price / CashN/A45.4837.2260.63Price / Book4.089.5614.066.31Net Income-$21.61M-$53.02M$3.29B$271.37M7 Day Performance-11.71%-1.58%-0.77%0.57%1 Month Performance-14.78%2.82%3.84%6.20%1 Year Performance10.11%9.34%87.65%28.33% Immix Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMXImmix Biopharma3.107 of 5 stars$1.96-2.0%$8.00+308.2%+8.3%$57.67MN/A-2.559AVIRAtea Pharmaceuticals1.7489 of 5 stars$2.86-3.9%$6.00+110.2%-27.6%$228.16MN/A-1.7970News CoverageShort Interest ↑SXTCChina SXT Pharmaceuticals1.3149 of 5 stars$1.95+4.0%N/A-60.4%$225.56M$1.74M0.0090Positive NewsShort Interest ↓HRTXHeron Therapeutics3.7044 of 5 stars$1.23-1.2%$4.50+267.3%-36.3%$224.57M$144.29M-61.25300PBYIPuma Biotechnology3.7658 of 5 stars$4.37-3.4%$7.00+60.4%+66.9%$220.92M$230.50M4.48200SOPHSOPHiA GENETICS2.2633 of 5 stars$3.27+1.1%$8.00+145.0%-18.8%$220.31M$65.17M-7.41520News CoveragePositive NewsCRGXCARGO Therapeutics1.6559 of 5 stars$4.47flat$15.40+244.5%N/A$216.17MN/A-0.96116PRQRProQR Therapeutics2.6101 of 5 stars$2.04+2.5%$8.00+292.2%+12.6%$214.63M$20.46M-4.43180Short Interest ↑GNFTGENFIT1.9217 of 5 stars$4.23-1.7%$9.00+113.0%-1.4%$211.25M$76.77M0.00120Positive NewsUpcoming EarningsGap DownAVTEAerovate TherapeuticsN/A$7.14+1.0%N/A-89.3%$206.95MN/A-2.3920High Trading VolumeTNYATenaya Therapeutics3.0377 of 5 stars$1.24-2.0%$6.25+406.1%-41.1%$201.28MN/A-1.29110 Related Companies and Tools Related Companies Atea Pharmaceuticals Competitors China SXT Pharmaceuticals Competitors Heron Therapeutics Competitors Puma Biotechnology Competitors SOPHiA GENETICS Competitors CARGO Therapeutics Competitors ProQR Therapeutics Competitors GENFIT Competitors Aerovate Therapeutics Competitors Tenaya Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMX) was last updated on 9/18/2025 by MarketBeat.com Staff From Our PartnersWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
